VEEV Stock Recent News

Next generation CRM with deep capabilities and agentic AI PLEASANTON, Calif. , Sept. 10, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Gilead Sciences has committed to Veeva Vault CRM.

The Investment Committee discuss the latest Calls of the Day.

I reiterate my 'Buy' rating on Veeva Systems, driven by accelerating Vault CRM adoption and robust R&D Solutions growth. VEEV's successful enterprise migrations and a 9-to-3 top-20 pharma win advantage over Salesforce reinforce its industry leadership. The resolution of the IQVIA dispute unlocks full Commercial Cloud potential, removing a major overhang and enabling integrated data solutions.

Zacks.com users have recently been watching Veeva (VEEV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

PLEASANTON, Calif. , Sept. 2, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced participation in the following investor conferences: Citi's 2025 Global TMT Conference, New York, NY.

Advanced regulatory capabilities and new industry partnerships accelerate collaboration with global health authorities PLEASANTON, Calif. , Sept. 2, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced more than 450 companies, including 19 of the top 20 biopharmas, have adopted Veeva RIM for regulatory information management (RIM) on a unified platform.

PLEASANTON, Calif. , Aug. 28, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a collaboration with Amgen to advance clinical trial innovation.

Veeva Systems Inc. (NYSE:VEEV ) Q2 2026 Earnings Conference Call August 27, 2025 5:00 PM ET Company Participants Brian Van Wagener - Chief Financial Officer Gunnar Georg Hansen - Director of Investor Relations Paul Shawah - Executive Vice President of Strategy & Campaign Manager Peter P. Gassner - Founder, CEO & Director Conference Call Participants Andrew Lodovico DeGasperi - BNP Paribas Exane, Research Division Brent Alan Bracelin - Piper Sandler & Co., Research Division Brian Christopher Peterson - Raymond James & Associates, Inc., Research Division Craig Matthew Hettenbach - Morgan Stanley, Research Division David E.

Evaluate the expected performance of Veeva (VEEV) for the quarter ended July 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Alnylam Pharmaceuticals, BeOne Medicines, Intercept Pharmaceuticals, Merck, Pfizer, and Sanofi among biopharmas sharing strategies that set future direction Veeva to showcase innovations, including deep industry-specific Veeva AI in Vault Platform and Veeva applications PLEASANTON, Calif. , Aug. 21, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced highlights of its upcoming Veeva R&D and Quality Summit, where leaders across life sciences and Veeva exchange impactful ideas and innovations.